The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
The new service delivers end-to-end support, managing every stage of an epigenomics project
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
Company to launch product after the expiry of semaglutide patent in India
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Subscribe To Our Newsletter & Stay Updated
